Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MVA-BN-CV301 |
| Trade Name | |
| Synonyms | MVA-BN CV301|MVA BN CV301|MVA-BN-CV-301 |
| Drug Descriptions |
MVA-BN-CV301 is a priming cancer vaccine derived from a modified vaccinia Ankara-Bavarian Nordic (MVA-BN) virus encoding CEA and MUC-1, as well as B7-1, ICAM-1, and LFA-3 costimulatory molecules (TRICOM), which potentially induces cytotoxic T-cell response against tumor cells expressing CEA and MUC-1 (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C143059 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 | Bintrafusp alfa FPV-CV301 MVA-BN-CV301 SX-682 | 0 | 1 |
| MVA-BN-CV301 | MVA-BN-CV301 | 0 | 0 |